Cerulean Pharma, a company that specializes in development and design of nanopharmaceuticals, declared that it has administered a dose of CRLX101 to the first group of patients as part of a random, non-small cell lung cancer (NSCLC) Phase 2 clinical study.
The chief aim of the Phase 2 experiment is to determine the safety and effectiveness of CRLX101 in advanced NSCLC patients who have received several courses of treatment previously. This study is expected to include around 150 patients at 26 clinical trial locations in Ukraine and Russia.
Patients will be treated in a random manner. They will receive either CRLX101 along with supportive care or only supportive care. Following this, patients will be studied based on tumor response, progression-free survival, overall survival, and pharmacokinetic parameters.
The President and CEO of Cerulean, Oliver Fetzer, stated that the company hopes to develop CRLX101 as a potential treatment for patients with lung cancer who have very few treatment alternatives.
The Chief Medical Officer of Cerulean, Edward Garmey, stated that clinical and preclinical data revealed the effectiveness of CRLX101 in squamous as well as non-squamous histology patient groups. He added that the CRLX101 has the potential to cure patients having different types of tumor mutational markers such as EGFR and KRAS.
Source: http://www.ceruleanrx.com/